معرفی
Professor David Vetrie serves as Professor of Translational Leukaemia Genomics at the Paul O'Gorman Leukaemia Research Centre, University of Glasgow, based at the Wolfson Wohl Cancer Research Centre. His research focuses on fundamental questions about regulatory processes controlling gene expression during normal haematopoietic development in both human and mouse models, and how these processes become dysregulated in leukemia.
Professor Vetrie's research interests center on gene regulation in normal haematopoietic development and disease. He employs state-of-the-art genomic approaches to investigate transcriptional and epigenetic processes both genome-wide and at specific gene loci. His work particularly focuses on understanding the changes in transcriptional and regulatory programs that occur during leukemia development and treatment, with special attention to leukemia stem cells and their role in therapeutic resistance.
Analysis of Professor Vetrie's recent publications reveals a strong thematic focus on leukemia stem cell biology, particularly in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). His research explores epigenetic regulation, immune evasion mechanisms, and therapeutic resistance, with an emphasis on developing novel targeted therapies to eliminate persistent leukemia stem cells. Key themes include the role of p53 signaling, epigenetic modifiers like EZH2 and KDM4A, and the bone marrow microenvironment in leukemia persistence.
Professor Vetrie has received substantial research funding from major organizations including Cancer Research UK, Medical Research Council, Blood Cancer UK, Wellcome Trust, Leukaemia UK, Children's Cancer and Leukaemia Group, and the European Commission. His current projects include identifying biomarkers predictive of TKI response in CML, functional analysis of leukemia stem cell subtypes, single-cell transcriptomics to combat chemoresistance in pediatric AML, and investigating parasitic worm products' influence on bone marrow progenitors.
